Tele: 561.316.3330
Breaking Medical Device News

Thursday, September 23, 2021

HomeMEDTRONIC plcMedtronic Statement Regarding IN.PACT Paclitaxel Safety Analysis Correction Letter in The Journal of the American College of Cardiology

Medtronic Statement Regarding IN.PACT Paclitaxel Safety Analysis Correction Letter in The Journal of the American College of Cardiology

Medtronic announced today that On February 15, 2019, they issued a statement regarding a programming error in the clinical data reporting isolated to the two and three year follow-up periods in our IN.PACT Global post-market study, part of the IN.PACT Admiral clinical program for the treatment of femoropopliteal artery disease.

In their previous statement, Medtronic said this programming error impacted the IN.PACT Paclitaxel Safety analysis, which recently presented at the Leipzig Interventional Course (LINC) in Leipzig, Germany and published online in the Journal of the American College of Cardiology (JACC).

The revised analysis has been accepted by JACC. Prior to publication of the revised  manuscript, the authors of the study have issued a correction letter addressing key revisions to the dataThe updated  analysis will also be presented by Dr. Peter Schneider at the VIVA Physicians Vascular Leaders Forum (VLF) from March 1-2, 2019 in Washington, D.C.

It is important to reiterate that the initial conclusions from the patient level meta-analysis remain intact:

  • Data found no correlation between paclitaxel dose and long-term survival.
  • Data demonstrated no difference in mean nominal dose of paclitaxel between overall survival in patients treated with DCB and those who died.
  • At five years there was no statistically significant difference in all-cause mortality between the drug-coated balloon (DCB)  and plain balloon angioplasty (PTA) arms.

In addition to the full  cohort, a standard cohort has been included by the authors in the JACC analysis. This was done to correct a baseline imbalance between DCB and PTA by identifying a subgroup of DCB patients who met the inclusion criteria for the  pivotal studies from the IN.PACT clinical program, including IN.PACT SFA, IN.PACT Japan, and IN.PACT China. When only the subjects that mirror the baseline variables in the control PTA group are included, we observe a smaller difference in mortality. When adjusted for these baseline imbalances, all-cause mortality between DCB and PTA was 13.2 percent vs 11 percent (p=0.188).

In line with our  commitment to transparency, we have shared all our patient-level data with FDA  in support of their paclitaxel safety analysis and will plan to do the same to support the upcoming independent VIVA Physicians analysis. Following publication of the revised JACC manuscript, we will also work to correct all impacted materials that live in the public domain.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy